Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis-Reference-Cited by-同舟云学术

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

Published:2019-12-03 Issue:2 Volume:10 Page:254-269
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Erkes Dan A.,Cai Weijia^ORCID,Sanchez Ileine M.,Purwin Timothy J.^ORCID,Rogers Corey,Field Conroy O.,Berger Adam C.,Hartsough Edward J.,Rodeck Ulrich,Alnemri Emad S.,Aplin Andrew E.^ORCID

Funder

HHS | NIH | National Cancer Institute

Dr. Ralph and Marian Falk Medical Research Trust

HHS | National Institutes of Health

U.S. Department of Defense

American Cancer Society

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 310 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of two different immune infiltrating pyroptosis subtypes in ischemic stroke;Heliyon;2024-09

2. DCS, a novel classifier system based on disulfidptosis reveals tumor microenvironment heterogeneity and guides frontline therapy for clear cell renal carcinoma;Journal of the National Cancer Center;2024-09

3. Colorectal Cancer with BRAF V600E Mutation: Trends in Immune Checkpoint Inhibitor Treatment;Critical Reviews in Oncology/Hematology;2024-09

4. Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors;Cancers;2024-08-27

5. Revisiting the potential of regulated cell death in glioma treatment: a focus on autophagy-dependent cell death, anoikis, ferroptosis, cuproptosis, pyroptosis, immunogenic cell death, and the crosstalk between them;Frontiers in Oncology;2024-08-09